> For the complete documentation index, see [llms.txt](https://doc.duaer.com/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://doc.duaer.com/guides/pharma-literature-search-ai-first-scenario-retry.md).

# How to Bring AI into Pharmaceutical Literature Search in 2027: Choosing the Right First Use Case

Adapted from the Duaer documentation site, this article breaks down the main challenges of pharmaceutical literature search, typical use cases, a method for prioritizing them, criteria for selecting a first pilot, and a practical workflow with metrics, for pharma teams planning enterprise AI adoption before 2027.

## Why Pharmaceutical Literature Search Is Hard

R&D, pharmacovigilance, medical affairs, and marketing teams in pharma run literature searches every day. A new target, a class of adverse events, or the latest clinical progress in an indication often means working through several databases and reading hundreds of abstracts. The real pain point is not only that relevant papers are hard to find. Searches are slow, papers get missed, and every finding still has to be checked manually against its source.

First, the terminology is complex. A single target may have abbreviations, full names, and aliases, and a drug may have a generic name, a brand name, and regional variants. A small error in the search string can produce very different results. Second, evidence quality is mixed. Reviews, case reports, conference abstracts, preprints, and peer-reviewed papers all show up together, so readers must first judge whether a source is trustworthy before they can ask what it actually shows. Third, the field moves quickly. Guidelines, regulatory notices, and newly published clinical data keep changing, and a review from last quarter may already be out of date. Fourth, results are hard to reproduce. Different people write different search strings, so when someone reruns a search, the resulting reference list often does not match.

Taken together, these challenges describe the real situation for most teams: searching depends on experience, screening depends on people, and tracing evidence depends on memory.

## Typical Use Cases and How to Prioritize Them

In a pharma company, literature search typically supports several scenarios: target and mechanism overviews for background research before a project is approved; competitor and pipeline tracking, which regularly reviews the progress of similar drugs; safety signal screening, which identifies adverse event reports in the literature; draft literature reviews for an indication, which provide material for submissions or internal reports; compiling evidence for labeling and regulatory dossiers, so that statements in the prescribing information are backed by sources; organizing academic conference and poster information into searchable records; and searching historical projects for existing conclusions in internal reports and past documents.

These scenarios have very different requirements and cannot be judged by a single standard. That is the premise for the prioritization step.

When ranking them, consider five dimensions: how often the question comes up each week, how much time manual searching and compilation take, the cost of an error, whether the required data is accessible, and whether the output has a clear human review step.

Take safety signal screening as an example. Its value is high, but so is the cost of error. Missing an important adverse event report can have serious consequences, so strict human review must stay in place, and implementation difficulty is medium to high. Competitor and pipeline tracking is the opposite. Its value is medium to high, the cost of error is relatively manageable, the data sources are clear, and the output format is fixed, which makes it a good starting scenario. Indication literature review drafts fall in between and are better tackled once the team has established solid search standards.

The goal of prioritization is not to pick the scenario with the greatest potential value. It is to find the one where value, difficulty, and risk all fall within what the team can handle.

## How to Choose the First Pilot

A first pilot should meet three criteria: the need comes up frequently, the results can be verified by people, and there is a clear judgment standard defined in advance. Competitor and pipeline tracking usually fits these criteria best.

Keep the scope narrow: one indication, one or two public data sources, and a clearly defined time window, with the pilot running for a few weeks. Before the pilot starts, senior researchers should build a test set by labeling a few dozen standard questions and listing the core papers each question should retrieve. During the pilot, avoid expanding the scope too quickly. Focus on whether the model retrieves the papers in the gold standard, whether its relevance judgments are reliable, and whether each conclusion can be traced back to a specific passage in the original paper.

For guidance on choosing a path, see [AI Drug R&D in 2027: Choosing the First Use Case That Pays Off](https://doc.duaer.com/guides/ai-pharma-research-first-use-case/). Its approach of seeing results first and expanding later can help you set specific, measurable pilot goals.

## Common Pitfalls and a Workable Process

Pitfall one: asking the model to summarize an answer without providing sources. In pharma, conclusions without sources are almost unusable. Reviewers have to search again, which adds to the workload. The right approach is to attach a reference ID, an excerpt from the original text, and the page or paragraph location to every conclusion.

Pitfall two: looking only at recall and ignoring review cost. If the system returns five hundred papers, coverage may look impressive, but if many of them are irrelevant, the screening burden on researchers has not decreased. What really matters is how many of the papers that end up in the final report were pre-screened by the system, and how many of those required manual correction.

Pitfall three: connecting every database and internal document from the start. More sources bring more noise, and problems become harder to isolate. Begin with a small scope, get the search strings, screening rules, and review workflow running smoothly, and then expand step by step.

A robust literature search workflow usually has six steps: standardize search string templates and define a terminology list with synonyms; retrieve candidate papers from each data source; classify candidates by relevance; keep the original excerpt and location information for each item; have researchers spot-check and correct the results; and archive everything as a traceable search record.

Every step should leave room for human judgment, especially relevance classification and review. These two steps should not be handed entirely to the model. If you want to put this workflow into practice, you can set up search, classification, and source traceability directly on [Duaer](https://www.duaer.com). Validate it on a single indication first, then decide whether to expand.

## How to Measure Results

The metrics do not need to be complicated. Consider five: how much of the gold standard literature the initial screen covers; the share of results corrected during human review; the time from question to finished reference list for a single search; the share of conclusions that can be traced back to the original text; and regular reviews of missed cases.

The first and fourth metrics are the most important. For how to reduce hallucinations and ensure every conclusion is backed by evidence, see [How to Curb LLM Hallucinations in 2027: Three Lines of Defense for Enterprise Knowledge Q&A](https://doc.duaer.com/guides/llm-hallucination-enterprise-qa-three-defenses/). The retrieval constraints and citation verification methods discussed there apply equally well to literature search.

## One Thing to Do This Week

Pick an indication your team is actively tracking. Collect the search strings your team used manually over the past month, along with the final list of selected papers. Then do two things: count how many searches were repeated, and identify important papers that were later found to be missing. Put these two numbers into a simple table. That table is your baseline for the first pilot. Without a baseline, no claimed efficiency gain can be measured.

If you would like help turning this scenario into an actionable rollout plan, you can sign up for a trial at [https://www.duaer.com](https://www.duaer.com) and start with a small literature search task.

Successful rollout depends on choosing the right first scenario and then safeguarding sources and review. Tell us about your literature search scenario, and we will send you a written rollout plan tailored to it.

https://api.duaer.com/form/1fea7709-3f8a-47f7-b4e3-eb5fb90e3213

## Questions

### Which scenario should a pharmaceutical company choose for its first AI pilot in literature search?

Competitor and pipeline tracking is usually the best starting point. The need comes up frequently, the data sources are clear, the output format is fixed, the cost of error is relatively manageable, and researchers can verify each result manually. Safety signal screening offers high value but also carries high error costs, so it is better suited to a later stage, once the workflow is mature and review mechanisms are solid.

### How can you ensure that AI-generated literature conclusions can be traced back to the original source?

Every conclusion should include a reference ID, an excerpt from the original text, and the page or paragraph location, and researchers should spot-check the results. Conclusions without sources are nearly unusable in pharma. For retrieval constraints and citation verification methods, refer to the three lines of defense for enterprise knowledge Q&A discussed in this article.

### What metrics should be used to evaluate an AI pilot for pharmaceutical literature search?

Track five metrics: how much of the gold standard literature the initial screen covers, the share of results corrected during human review, the time from question to finished reference list, the share of conclusions traceable to the original text, and regular reviews of missed cases. Coverage and traceability are the most critical. Before the pilot begins, collect the past month's search strings and selected papers from your team to serve as a comparison baseline.

